Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07039461 · ClinicalTrials.gov registry record · NA
Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion
A NA study, sponsored by Lumenis Be.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT07039461: Clinical Trial NA study, sponsored by Lumenis Be.
NCT07039461 is a NA study that was terminated before completion, run by Lumenis Be. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07039461, a NA study, was terminated before completion, sponsored by Lumenis Be.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
To study the effectiveness and safety of IPL treatment for Chalazion
Primary Outcome
the proportion of subjects with reduction of at lease 80% in lesion size at the follow up visit
Interventions
- DEVICE OptiLIGHT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2025-12-24 |
| Phase | NA |
Why NCT07039461 stopped before completion
NCT07039461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which OptiLIGHT is the first listed.
NCT07039461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07039461 about?
NCT07039461 is a clinical study titled "Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion". To study the effectiveness and safety of IPL treatment for Chalazion
What is the current status of trial NCT07039461?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2025-09-12. Estimated completion is 2025-12-24.
What interventions are being tested in trial NCT07039461?
The interventions under investigation include: OptiLIGHT (DEVICE).
Who is sponsoring clinical trial NCT07039461?
This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07039461's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI